Elevated circulating IL-32 presents a poor prognostic outcome in patients with heart failure after myocardial infarction

IL-32 might be a novel predictor of adverse cardiac event in patients with HF after MI. The pro-fibrotic effect of IL-32 may contribute to adverse cardiac remodeling and progression to HF.